Improvements in Functional Class and Ejection Fraction with Adherence to Heart Failure Treatment Guidelines

2009 ◽  
Vol 18 ◽  
pp. S179
Author(s):  
R. Sanders ◽  
D. Prior
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Treatment Guidelines ◽  
Functional Class ◽  
Heart Failure Treatment ◽  
Failure Treatment

Subacute Doxorubicin-Induced Cardiomyopathy with Reduced Ejection Fraction and Optimal Recovery of Left Ventricular Ejection Fraction After Medical Heart Failure Treatment

2018 ◽  
Vol 273 ◽  
pp. 6 ◽  
Author(s):  
Wan Faizal Wan Rahimi Shah ◽  
Mohamed Nazrul Mohamed Nazeeb ◽  
Ahmad Farhan Abdul Hamid ◽  
Teoh Chee Kiang ◽  
Emily Tan Lay Koon ◽  
...  
Keyword(s):  
Heart Failure ◽  
Left Ventricular Ejection Fraction ◽  
Ejection Fraction ◽  
Optimal Recovery ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Heart Failure Treatment ◽  
Ventricular Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
Failure Treatment

scholarly journals Clinical, paraclinical characteristics and real –world treatment of acute heart failure at Hanoi Heart Hospital

2021 ◽  
Vol 35 ◽  
pp. 233-242
Author(s):  
Vu Quynh Nga ◽  
Tran Thanh Hoa ◽  
Nguyen Van Son
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Treatment Guidelines ◽  
Artery Bypass ◽  
Severe Illness ◽  
Assisted Circulation ◽  
Heart Failure Treatment ◽  
Failure Treatment ◽  
Number Of Patients ◽  
Heart Hospital

Background: At Hanoi Heart Hospital, in recent years, along with the development of science and technology, the development of modern treatment measures such as percutaneous coronary intervention, coronary artery bypass surgery, heart valve replacement ... helped save the lives of many patients. However, these patients still require continued treatment for heart failure as a complication of the primary illness and thus also increase the number of patients with heart failure, both acute and decompensated. Objective: “Describe the clinical and subclinical characteristics of hospitalized patients with acute heart failure and the status of heart failure treatment according to current heart failure treatment guidelines at Hanoi Heart Hospital”. Method: Cross-sectional, prospective, descriptive analysis with convenient sample size. Results: From January 2018 to december 2018, 475 patients were hospitalized due to acute heart failure or decompensation ,63,8% male and 36, 2% female. Mean age 69,1 ± 13,8;  63,6% newly discovered heart failure; 41,4% EF 40 – 50% and 58,6% EF < 40%; number of Hopital days 8.3 ± 6.2 days(( 1- 46 days); there are five (1.1%) patients died in hospital; among them a patient who was treated for one day due to severe illness died; we have used interventions, assisted circulation and respiration such as CRT, CRT-D, CVVH, IABP, atrial septal defect and ECMO. Conclusion: Results of treatment of acute heart failure at Hanoi Heart Hospital is feasible with rate of discharge is 87,7%.

scholarly journals Teaching Heart Failure Treatment Guidelines and Assessing Heart Failure Therapy

2010 ◽  
Vol 74 (6) ◽  
pp. 103 ◽  
Author(s):  
Kathleen A. Packard ◽  
Thomas L. Lenz ◽  
Christopher J. Destache
Keyword(s):  
Heart Failure ◽  
Treatment Guidelines ◽  
Heart Failure Therapy ◽  
Heart Failure Treatment ◽  
Failure Treatment

scholarly journals 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction

2018 ◽  
Vol 71 (2) ◽  
pp. 201-230 ◽  
Author(s):  
Clyde W. Yancy ◽  
James L. Januzzi ◽  
Larry A. Allen ◽  
Javed Butler ◽  
Leslie L. Davis ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Expert Consensus ◽  
Heart Failure Treatment ◽  
Reduced Ejection Fraction ◽  
Failure Treatment ◽  
Consensus Decision

scholarly journals Adherence to European Society of Cardiology Heart Failure Treatment Guideline in Haji Adam Malik General Hospital Medan

2020 ◽  
Vol 3 (1) ◽  
pp. 59-64
Author(s):  
Ardy Putra Wirtanto ◽  
Andika Sitepu
Keyword(s):  
Heart Failure ◽  
European Society ◽  
Treatment Guidelines ◽  
Beta Blockers ◽  
Treatment Guideline ◽  
Public Health Problem ◽  
Cross Sectional ◽  
Heart Failure Treatment ◽  
Failure Treatment ◽  
European Society Of Cardiology

Background. Heart failure is a public health problem and the main cause of morbidity and mortality in the world. The goal of the therapy is to reduce symptoms, prevents rehospitalization and increases survivability. Objective. To evaluate the adherence to the European Society of Cardiology for heart failure treatment at H. Adam Malik Medan hospital. Methods. The study was descriptive observational cross sectional design with medical record data of heart failure at H. Adam Malik Hospital, using consecutive sampling method. The adherence of guidelines was assessed by: (1) drug prescribing (“yes” or “no”), and (2) guideline adherence indicator (GAI), both GAI-3 or GAI-5, by calculating the proportion as the number of drugs prescribed by number of drugs indicated to the ESC guidelines. Results. From research, the predominant GAI-3 and GAI-5 were High, which were 54.9% and 59.5%, respectively. The recommended drug used based on indications were ACE-i / ARB (89.1%), beta-blockers (83.4%), MRA (73.6%), diuretics (93.7%), and digitalis (20,8%). Conclusion. The predominant category in adherence to the ESC heart failure treatment guidelines based on GAI-3 and GAI-5 is High.

scholarly journals Heart failure on peritoneal dialysis: Where do we stand?

2021 ◽  
Vol 35 (3) ◽  
Author(s):  
Marina Reis ◽  
◽  
Catarina Almeida ◽  
Ana Gomes ◽  
João Fernandes ◽  
...  
Keyword(s):  
Heart Failure ◽  
Peritoneal Dialysis ◽  
Ejection Fraction ◽  
Left Ventricular ◽  
New Drugs ◽  
Preserved Ejection Fraction ◽  
Dialysis Patients ◽  
Heart Failure Treatment ◽  
Failure Treatment ◽  
Uremic Cardiomyopathy

Cardiovascular disease continues to be the most frequent cause of death in peritoneal dialysis patients and an important obstacle for the improvement of technique survival. Heart failure diagnosis and management is particularly challenging among dialysis patients, and this condi‑ tion remains underdiagnosed and undertreated in this population. The most common phenotype of heart failure among peritoneal dialysis patients is heart failure with preserved ejection fraction, diastolic disfunction and left ventricular hypertrophy. Unfortunately, unlike what happens with heart failure with reduced ejection fraction, there is lack of evidence to support a specific drug regimen to treat heart failure with preserved ejection fraction. Several conditions associated with end stage kidney disease, such as anemia, hyperphosphatemia, secondary hyperparathyroidism, inflammation, and insulin resistance seem to be involved in the pathogenesis of heart failure with preserved ejection fraction and for this reason, the term uremic cardiomyopathy has been proposed. There is a lack of evidence regarding the optimal heart failure treatment for peritoneal dialysis patients and more studies are needed to assess the efficacy and safety of the new drugs available for heart failure treatment. This review explores the spectrum of heart failure on peritoneal dialysis, its pathogenesis, risk factors and possible therapeutic and preventive measures.

Abstract 1614: Sequential Analysis of Immunosuppressive Therapy in Autoreactive Myocarditis - Sequential Analysis from ESETCID

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Bernhard Maisch ◽  
Sabine Pankuweit ◽  
Susanne Koelsch ◽  
Guenther Hufnagel ◽  
Reinhard Funck ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Sequential Analysis ◽  
Nyha Class ◽  
Icd Implantation ◽  
Heart Failure Treatment ◽  
Cardiac Decompensation ◽  
Failure Treatment ◽  
Persistent Inflammation

In the European Study on Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID) pts with autoreactive (virus-negative) myocarditis (AM) and an ejection fraction <45% were randomised for 6 months of treatment with azathioprin (2mg/kg BW/day for 1 m and 0.85mg/kg BW/day for 5 m) + prednisolone (1.25mg/kg BW/ for 1 m and 0.3mg/kg BW/day for 5 m) or placebo on top of their heart failure treatment and followed-up for up to 8 years. Patients: 3149 pts with dilated cardiomyopathy were screened, 103 pts (mean age 47± 9 years, 81 male, 22 female) with AM and an EF 14 infiltrating cells/mm 2 ), persistence of viral or bacterial genomes for Parvo B19, coxsackie-, influenza-, adeno-, cytomegalo-, HHV 6, EBV, chlamydia and borrelia were excluded from the analysis. 56 pts (45 m) with AM were treated with verum, 47 pts ( 38m) with placebo. MACE are defined as cardiac death, heart transplantation, ICD implantation or hospitalisation for cardiac decompensation. Time to MACE is given in days to the event. Results: Inflammation was eradicated in 63% in the treatment group, but it also vanished spontaneously in 40% in the placebo arm(p<0,05). After 12 months the Kaplan Mayer MACE curves began to diverge. At 4 years freedom from MACE was 50% in the verum and 40% in the placebo group. Respective data at 8 years were 40% and 20% freedom from MACE. NYHA-association class and Minnesota Heart Failure Score improved in treatment and placebo arms to a similar extend. Ejection fraction by echo and radioventriculography improved in both arms with a trend for immunosuppression(IS). Independent from IS pts with no inflammation in the follow-up biopsy (n=45) showed a better NYHA-class (p<0,05), ejection fraction and superior long term freedom from MACE than those with persistent inflammation.. Conclusion: Immunosuppression is superior to conventional heart failure treatment in the acute eradication of the inflammatory infiltrate iDCM patients and bears better long-term prognosis. Results

scholarly journals Adherence to the ESC Heart Failure Treatment Guidelines in Spain: ESC Heart Failure Long-term Registry

2015 ◽  
Vol 68 (9) ◽  
pp. 785-793
Author(s):  
María G. Crespo-Leiro ◽  
Javier Segovia-Cubero ◽  
José González-Costello ◽  
Antoni Bayes-Genis ◽  
Silvia López-Fernández ◽  
...  
Keyword(s):  
Heart Failure ◽  
Treatment Guidelines ◽  
Heart Failure Treatment ◽  
Failure Treatment
Sign in / Sign up

Export Citation Format

Share Document